Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Идиопатическая тромбоцитопеническая пурпура (ИТП) у взрослых

Список литературы

  1. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood. 2009; 113(11): 2386--93. doi: 10.1182/blood-2008-07-162503.
  2. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. PresseMed.2014; 43(4 Pt2): e49-59. doi:10.1016/j.lpm.2014.01.010
  3. Меликян А.Л., Пустовая Е.И., Калинина М.В., Володичева Е.М., Капорская Т.С., Ильясов Р.К., Бабаева Т.Н., Беккер О.М., Богова В.С., Зотина Е.Н., Зотова И.И., Контиевский И.Н., Пяткова О.А., Соколова И.С., Федорова Н.А., Шестопалова И.А., Колошейнова Т.И., Егорова Е.К., Куликов С.М. Эпидемиологические характеристики первичной иммунной тромбоцитопении у взрослого населения в Российской Федерации. Клиническая онкогематология. Фундаментальные исследования и клиническая практика.  2017; №4 (10): 558-559.
  4. Provan D., Stasi R., Newland A.S., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168--86.doi: 10.1182/blood-2009-06-225565.
  5. Neunert C., Lim W., Crowther M., Cohen A., Solberg L.Jr., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190--207. doi: 10.1182/blood-2010-08-302984.
  6. МасчанА.А., Румянцев А.Г., Ковалева Л.Г., Афанасьев Б.В., Поспелова Т.И., ЗарицкийА.Ю. и др. Рекомендации Российского совета экспертов по диагностике и лечению больных первичной иммунной тробоцитопенией. Онкогематология. 2010; 3: 36-45.
  7. Ковалева Л.Г., Пустовая Е.И., Сафонова Т.И. Идиопатическая тромбоцитопеническая пурпура (ИТП) взрослых. Первичная иммунная тромбоцитопения (ИТП) взрослых. Болезнь Верльгофа. М.: Нью Мун; 2014.
  8. Меликян А.Л., Пустовая Е.И., Егорова Е.К., Калинина М.В., Колошейнова Т.И., Суборцева И.Н., Гилязитдинова Е.А., Двирнык В.Н. Дифференциальная диагностика тромбоцитопений. Онкогематология. 2017;12(1): 78-87.  
  9. Provan D., Arnold D., Bussel J.B., Chong B.H., Cooper N., Gernsheimer T., Ghanima W., et.al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood advances. 2019;3(22):3780--3808. doi: 10.1182/bloodadvances-2019000812.
  10. Kurokawa T., Ohkohchi N. Ohkohchi Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017 May 14; 23(18): 3228–3239.  PMID: 28566882 doi: 10.3748/wjg.v23.i18.3228
  11. Protocole national de diagnostic et de soins (PNDS)  Purpura thrombopenique immunologiquede l’enfant et de l’adulte. Haute Autoritéde Santé – Mai 2017, 73p.
  12. Carneiro-Sampaio M., Moraes-Vasconcelos D., Kokron C.M., Jacob C.M., Toledo-Barros M., Dorna M.B., et al. Primary immunodeficiency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J. Clin. Immunol. 2013; 33(4): 716--24.
  13. Michel M., Cooper N., Jean C., Frissora C., Bussel B. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 2004, 103(3):890-896. Doi:10.11.1182/blood-2003-03-0900.
  14. Liu Y., Chen S., Sun Y., Lin Q., Liao X., Zhang J., Luo J, Quian H., Shi G. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. 2016 Dec;95(50):e5565.
  15. Matzdorff  A., Eberl W., Kiefel V., Kühne T., Meyer O., Ostermann H., Pabinger-Fasching I., Rummel M.J., Wörmann B. Immunthrombozytopenie (ITP). Onkopedia leitlinien– 2018, 46 p.
  16. Wei Y., Ji X.B., Wang Y.W., Wang J.X., Yang E.Q., Wang Z.C., Sang Y.Q., et.al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016 Jan 21;127(3):296-302; quiz 370. doi: 10.1182/blood-2015-07-659656.
  17. Kovaleva L, Apte S, Damodar S, et al; investigators of the Flebogamma DIF in ITP Study Group. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies.Immunotherapy.2016;8(12): 1371-1381.
  18. Stasi R. How to approach thrombocytopenia. Hematology Am Soc HematolEduc Programm2012; 2012:191-7. Doi :10.1182/ash education-2012.1.191.
  19. Von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988;296(6617):249-250.
  20. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2;120(5):960-9. doi: 10.1182/blood-2011-12-309153.
  21. Frenzel W, Wietek S, Svae TE, Debes A, Svorc D. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther.2016;54(11):847-855.
  22. Robak T, Salama A, Kovaleva L, et al; International Privigen in ITP Study Group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology.2009;14(4):227-236.
  23. Robak T, Mainau C, Pyringer B, et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia. Hematology.2010;15(5):351-359.
  24. Cines D.B., McMillan R. Management of adult idiopathic thrombocytopenic purpura.Annu.Rev.Med. 2005;56:425-42. doi:10.1146/annurev.med.56.082103.104644
  25. Neunert C., Terrell D.R., Arnold D.M., Buchanan G., Cines D.B., Coopr N., et al.American Society of Hematology 2019guidelinesfor immune thrombocytopenia. Blood Adv. 2019;3(23):3829--3867. doi: 10.1182/bloodadvances.2019000966.
  26. Carr A.C., Maggini S. Review Vitamin C and Immune Function. Nutrients 2017, 9, 1211; doi:10.3390/nu9111211
  27. Тимирханова Г.А., Абдуллина Г.М., Кулагина И.Г. Витамин С: классические представления и новые факты о механизмах биологического действия. Вятский медицинский вестник.2007, №4. Актуальные вопросы современной биохимии. 3:158-161.
  28. Козярин И.П., Липкан Г.Н., Мвахно А.П. Жгучая, но полезная. Крапива двудомная - лекарственное и пищевое растение (обзор литературы). Гiгiена населених мiсць. 2013; 62:246-250  УДК:615.322:582.635.5:613.26
  29. Данишян К.И., Соболева О.А., Галстян Г.М., Зверева А.В., Соркина О.М. Лапароскопическая спленэктомия при иммунной тромбоцитопенической пурпуре у беременных. Терапевтический архив, 2016; 7: 109-113.  
  30. Карагуюлян С.Р., Данишян К.И., Шутов С.А., Силаев М.А. Технические сложности выполнения спленэктомии при заболеваниях системы крови. Кдиническая онкогематология. 2017; 10(1):101-7. doi:10.21320/2500-2139-2017-10-1101-107.
  31. Vianelli N., Palandri F., Polverelli N., Stasi R., Joelsson J., Johansson E., Ruggeri M., Zaja F. et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica.2013;98(6):875-880.
  32. Vianelli N., Galli M., de Vivo A., Intermesoliti T., Giannini B., Mazzucconi M.G., et.al, Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90(1): 72-77.
  33. Park Y.H., Yi H.G., Kim C.S., et al; Gyeonggi/Incheon Branch, The Korean Society of Hematology. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study. Acta Haematol. 2016;135(3):162-171.
  34. Tada K, Ohta M, Saga K, et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today.2018;48(2): 180-185.
  35. Chater C, Terriou L, Duhamel A, et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016;264(5):772-777.
  36. Vecchio R, Marchese S, Intagliata E, Swehli E, Ferla F, Cacciola E. Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. J Laparoendosc Adv Surg Tech A.2013;23(3):192-198.
  37. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood.2013;121(23):4782-4790.
  38. Thai LH, Mahevas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia.Medicine (Baltimore).2016; 95(48):e5098.
  39. Choi YU, Dominguez EP, Sherman V, Sweeney JF. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. JSLS.2008;12(3):314-317.
  40. KuterD.J., BusselJ.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia safety and efficasy. Br.J.Haematol. 2013; 161(3): 411-23. doi: 10.1111/bjh.12260. 
  41. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. BrJ Haematol.2016;172(2):262-273.
  42. Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ. Remissions after long-term use of romiplostim for immune thrombocytopenia.Haematologica.2016;101(1 2):e476-e478.
  43. Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica.2017;102(8):1342-1351.
  44. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.     
  45. BusselJB, Saleh MN, Vasey SY, Mayer B, ArningM, Stone NL. Repeated short-term use of eltrombopagin patients with chronic immune thrombocytopenia (ITP). BrJ Haematol. 2013 Feb;160(4):538-46. doi: 10.1111/bjh.12169.
  46. Cheng G., Saleh M.N., Marcher C., Vasey S., Mater B., Aivado M., et.al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393-402. doi: 10.1016/S0140-6736(10)60959-2.
  47. Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol.2018;84(11):2673-2677.
  48. Gonzalez-Lopez TJ, Fernandez-Fuertes F, Hernandez-Rivas JA, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol.2017;106(4):508-516.
  49. Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost.2012;10(5):799-806.
  50. Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol.2016;97(3):297-302.
  51. Gonzales-Porras J.R., Mingot-Castellano M.E., Andrade M.M., Alonso R., CaparrosI., et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. BrJHematology, 2015, 169, 111-116. Doi 10.1111/bjh.13266
  52. Khellaf M., Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F., Lefrere F, et.al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013; 98(6):881-7. Doi: 10.3324/haematol.2012.074633. 
  53. Kuter DJ, Macahilig C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3):255-263.
  54. Puavilai T. et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta‐analysis //British journal of haematology. – 2020. – Т. 188. – №. 3. – С. 450-459.
  55. Cervinek L, Cerna O, Caniga M, et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol.2012;96(5):594-599. doi: 10.1007/s12185-012-1206-7.
  56. Hai Zhou et al. A multicenter randomized open-label study of rituximab plus rhTPOvs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541-7. doi: 10.1182/blood-2014-06-581868.
  57. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood.2014;124(22):3228-3236. doi: 10.1182/blood-2014-06-582346.
  58. Arnold DM, Heddle NM, Carruthers J et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomisedpatients with immune thrombocytopenia. Blood. 2012; 119:1356-1362
  59. GhanimaW, KhelifA, WaageA et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicenter, randomised, double blind, placebo-controlled trial. Lancet 2015; 385:1653-1661  dx.doi.org/10.1016/S0140-6736(14)61495-1
  60. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol.2015;2(2):e75-e81.
  61. Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood.2012;119(25):5989-5995.
  62. Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol.2017;98(4):371-377.
  63. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis.2009; 27(3):329-333.
  64. Mahevas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol.2013;88(10):858-861.
  65. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol.2010;85(4):329-334.
  66. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood.2010;115(1):29-31.
  67. Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol.2013;90(6):494-500.
  68. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood.2013;121(11):1976-1981.
  69. Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol.2016;91(9):907-911.
  70. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.Haematologica.2014;99(7):1 264-1271.
  71. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им.Н.И.ПироговаМинздрава России, 2016г., 94 с.
  72. Piel-Julian ML, Mahesvas M, Germain J, et al; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost.2018;16(9):1830-1842.  doi: 10.1111/jth.14227.
  73. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013 Jan 3;121(1):38-47. doi: 10.1182/blood-2012-08-448944.
  74. Васильев С.А., Виноградов В.Л., Мазуров А.В., Маркова М.Л. Тромбоцитопении. Акушерство, гинекология и репродукция. 2014; № 2: с.112-125.
  75. Sukenik-Halevy R1, Ellis MH, FejginMD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008 Mar;63(3):182-8. doi: 10.1097/OGX.0b013e318164013c.
  76. George JN, Nester C, McIntosh J Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hem Education Program, 2015, Dec 5, 644-8
  77. Fakhouri F. Pregnancy-related thrombotic microangiopathies:  clues from complement biology, Transfusion and ApheresSci, 2016, 54, p 199-202
  78. Кирсанова Т.В, Виноградова М.А, Федорова Т А, Имитаторы тяжелой преэклампсиии HELLP синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью.  Акушерство и гинекология, 2016,  12, с 5-14

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*